MedTrace Logo

ERN ReCONNET Study on COVID-19 Vaccination in Rare and Complex Connective Tissue Disease (VACCINATE)

NCT04702295 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2021-01-08

No results posted yet for this study

Summary

30 months, multicentre, prospective observational study on adult (\>18 years) patients with a diagnosis of rare and complex connective tissue diseases (rCTDs) who will be given the vaccine during the period from January 2021 and January 2022.

Patients with the following diagnosis will be included:

* antiphospholipid syndrome (APS),
* Ehlers-Danlos syndrome (EDS),
* idiopathic inflammatory myopathies (IIM),
* IgG4-related disease (IgG4),
* mixed connective tissue disease (MCTD),
* relapsing polychondritis (RP),
* Sjogren's syndrome (SS),
* systemic lupus erythematosus (SLE),
* systemic sclerosis (SSc)
* undifferentiated connective tissue disease (UCTD)

Conditions

  • Connective Tissue Diseases
  • Rare Diseases
  • Rheumatologic Disorder

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2023-02-28
Completion
2023-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702295 on ClinicalTrials.gov